Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25475800 | 0.90 | ALDH1A1 (0.40) | ALDH1A1TDP1 | |
| SCHEMBL10212356 | 0.90 | BHMT (0.37) | TDP1CYP2C19 | |
| SCHEMBL19222595 | 0.89 | ALDH1A1 (0.32) | ALDH1A1TDP1 | |
| SCHEMBL25551254 | 0.86 | CYP2C19 (0.36) | ALDH1A1TDP1CYP2C19CA2 | |
| SCHEMBL26003302 | 0.86 | TDP1 (0.38) | TDP1 | |
| SCHEMBL12977350 | 0.85 | CA1 (0.38) | ALDH1A1TDP1CA2 | |
| SCHEMBL26003256 | 0.84 | — | — | |
| SCHEMBL24941917 | 0.83 | CA12 (0.33) | CA2 | |
| SCHEMBL888859 | 0.82 | — | — | |
| SCHEMBL1697333 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | STARPHARMA PTY LTD (AU) | 2023-08-24 | — | — | US | disclosed |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | STARPHARMA PTY LTD (AU) | 2023-08-24 | — | — | US | disclosed |
| US-10689430-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | ALDH1A1 4716/4885TDP1 4818/4885CYP2C19 2775/4885 |
| US-10689430-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | ALDH1A1 4716/4885TDP1 4818/4885CYP2C19 2775/4885 |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | SARS1, MMAB, PAM | ALDH1A1 2061/4885TDP1 3076/4885CYP2C19 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.